369 results about "Therapy eye" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a grasping body having a longitudinal axis, and a piercing member coupled to the grasping body, including an elongate body and a beveled piercing tip including a long side and a short side, wherein the piercing member includes a proximal segment, a distal segment, and an aperture nested between the proximal segment and the distal segment, wherein the short side and the aperture are coaxially disposed along a central longitudinal axis of the piercing member, and wherein the piercing member is configured to reciprocate along the longitudinal axis relative to the grasping body.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

An ophthalmic lens configured to correct and / or treat at least one condition of the eye (e.g., presbyopia, myopia, hyperopia, astigmatism, binocular vision disorders, night vision image quality, and / or visual fatigue syndrome) comprising: a base power profile; and at least one pulse selected to modify the base power profile.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

An example wearable mask includes a first coverage portion including a first front side and a first back side opposite the first front side. The first front side is configured to contact a first portion of a body of a user when the wearable mask is worn, and the first back side is configured to be directed away from the first portion when the wearable mask is worn. The first coverage portion further includes a first opening, a second opening, and a first passageway extending from the first opening to the second opening. The wearable mask further includes a strap extending through the first passageway. The first coverage portion is movably attached to the strap.

A portable, handheld device and electrodes deliver precise electrical stimulation to targeted areas around the skin of the face and eyelids to treat ocular conditions. The micro stimulation device generates microcurrent using a current generator. One or more electrodes are electrically coupled to the micro stimulation device and contact and conduct the microcurrent to the facial and / or ocular skin of a patient. The current generator is configured to generate the microcurrent at a selected one of a plurality of power levels, wherein the plurality of power levels includes: 250 microamps (μA), 500 μA, 750 μA, 1000 μA, 1250 μA, and 1500 μA. A first user input is configured for a user to select one of the plurality of power levels.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

An ophthalmological device and system is described that allows the simultaneous imaging of an eye using both scanning laser ophthalmoscopy (SLO) and optical coherence tomography (OCT). Further the device and system is capable of targeting and delivering a treatment laser for treatment of an eye condition.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

The invention relates to a photoreceptor cell specific bidirectional promoter and application thereof. Specifically, the invention relates to a novel photoreceptor cell specific bidirectional promoter, an expression cassette containing the bidirectional promoter, a vector, a viral particle, a cell and a pharmaceutical composition, and application of the bidirectional promoter to treatment of eye diseases, such as retinal diseases.

The invention provides methods of treating an eye disorder and compositions for use therein, the methods comprising applying a crosslinkable liquid composition onto an anterior corneal surface of said eye using a mold; crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a crosslinked composition on the anterior corneal surface of the eye; and correcting the curvature of the crosslinked composition.

The invention relates to a computer-implemented method for calculating an intraocular lens (IOL). The method comprises calculating the IOL based on a biometric parameter of an eye to be treated with the IOL. Calculating the IOL involves taking into account the following: an expected change to the intraocular pressure as a result of treating the eye to be treated with the IOL compared to an intraocular pressure of the eye to be treated prior to treating the eye to be treated with the IOL; an expected intraocular pressure after treating the eye to be treated with the IOL; and / or an intraocular pressure prior to treating the eye to be treated with the IOL.

A system for the treatment of the dry eye syndrome that is based on a light source. The system includes a disposable tip, to treat an eyelid. A corneal shield is used to protect the patient's eye.

Provided herein are methods for treating conditions in or around the eye with a pharmaceutical composition comprising a keratolytic agent by spreading the pharmaceutical composition prior to administering the pharmaceutical composition to an ocular or periocular surface (e.g., eyelid) of an individual in need thereof.

Formulations and intravitreal implants containing nintedanib can be used in methods of treating diseases of the posterior portion of the eye.

Provided herein is a method of delivering a pharmaceutical composition comprising an AAV vector to an ocular or periocular tissue, comprising injecting the AAV vector periocularly (e.g., periocular injection, optionally peribulbar injection). In some aspects, the method is for use in treating an ophthalmic pathology (e.g., thyroid eye disease (TED) in a subject in need thereof.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

Provided are cell models of eye diseases, methods and compositions for treating eye diseases.

A source of light energy such as a source of violet light energy is coupled to a structure configured to contact the eye. The light source and structure are arranged to provide therapeutic amounts of violet light energy to the eye in order to inhibit the progression of refractive error such as myopia. The light source can be configured in many ways and may comprise a radioisotope and a phosphorescent material. The structure configured to contact the eye may comprise a contact lens or an implant.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral, amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.